O Shaughnessy Asset Management LLC Sells 561 Shares of Eli Lilly and Company (NYSE:LLY)

O Shaughnessy Asset Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 107,976 shares of the company’s stock after selling 561 shares during the period. Eli Lilly and Company comprises about 0.7% of O Shaughnessy Asset Management LLC’s investment portfolio, making the stock its 21st biggest position. O Shaughnessy Asset Management LLC’s holdings in Eli Lilly and Company were worth $83,357,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Prevail Innovative Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $3,628,000. Physician Wealth Advisors Inc. raised its holdings in Eli Lilly and Company by 23.2% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,406 shares of the company’s stock valued at $1,085,000 after acquiring an additional 265 shares during the period. Martin Currie Ltd. lifted its position in shares of Eli Lilly and Company by 137.9% during the fourth quarter. Martin Currie Ltd. now owns 37,422 shares of the company’s stock worth $28,890,000 after acquiring an additional 21,689 shares in the last quarter. RWA Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.3% in the fourth quarter. RWA Wealth Partners LLC now owns 45,191 shares of the company’s stock worth $34,888,000 after acquiring an additional 1,028 shares during the period. Finally, Schroder Investment Management Group grew its position in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Schroder Investment Management Group now owns 1,686,582 shares of the company’s stock valued at $1,302,041,000 after purchasing an additional 5,369 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $820.30 on Friday. The stock has a market cap of $777.78 billion, a price-to-earnings ratio of 70.05, a PEG ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock’s 50 day simple moving average is $844.31 and its two-hundred day simple moving average is $836.37. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.